207 related articles for article (PubMed ID: 26555472)
1. Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition.
Tie C; Gao K; Zhang N; Zhang S; Shen J; Xie X; Wang JA
PLoS One; 2015; 10(11):e0142430. PubMed ID: 26555472
[TBL] [Abstract][Full Text] [Related]
2. Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice.
Guo X; Wang L; Xia X; Wang P; Li X
Biomed Pharmacother; 2019 Jan; 109():1445-1453. PubMed ID: 30551396
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Antiatherogenic Properties of Ezetimibe Using
Dumas LS; Briand F; Clerc R; Brousseau E; Montemagno C; Ahmadi M; Bacot S; Soubies A; Perret P; Riou LM; Devoogdt N; Lahoutte T; Barone-Rochette G; Fagret D; Ghezzi C; Sulpice T; Broisat A
J Nucl Med; 2017 Jul; 58(7):1088-1093. PubMed ID: 28280218
[TBL] [Abstract][Full Text] [Related]
4. Effects of ezetimibe on atherosclerosis in preclinical models.
Davis HR; Lowe RS; Neff DR
Atherosclerosis; 2011 Apr; 215(2):266-78. PubMed ID: 21397230
[TBL] [Abstract][Full Text] [Related]
5. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T
Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in LDLr-/- mice.
Eussen SR; Rompelberg CJ; Andersson KE; Klungel OH; Hellstrand P; Oste R; van Kranen H; Garssen J
Pharmacol Res; 2011 Jul; 64(1):36-43. PubMed ID: 21371558
[TBL] [Abstract][Full Text] [Related]
7. Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to Atorvastatin (40 mg) Alone on Coronary Atherosclerosis.
Oh PC; Jang AY; Ha K; Kim M; Moon J; Suh SY; Lee K; Han SH; Kang WC
Am J Cardiol; 2021 Sep; 154():22-28. PubMed ID: 34238445
[TBL] [Abstract][Full Text] [Related]
8. Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin.
Salic K; Morrison MC; Verschuren L; Wielinga PY; Wu L; Kleemann R; Gjorstrup P; Kooistra T
Atherosclerosis; 2016 Jul; 250():158-65. PubMed ID: 27236706
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice.
Yang LX; Heng XH; Guo RW; Si YK; Qi F; Zhou XB
J Cardiovasc Pharmacol; 2013 Aug; 62(2):205-11. PubMed ID: 23615158
[TBL] [Abstract][Full Text] [Related]
10. [Atorvastatin inhibits the atherosclerotic lesion induced by tumor necrosis factor-like weak inducer of apoptosis in apolipoprotein E deficient mice].
Fernández-Laso V; Sastre C; Egido J; Martín-Ventura JL; Blanco-Colio LM
Clin Investig Arterioscler; 2015; 27(1):17-25. PubMed ID: 25027757
[TBL] [Abstract][Full Text] [Related]
11. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect.
Gómez-Garre D; Muñoz-Pacheco P; González-Rubio ML; Aragoncillo P; Granados R; Fernández-Cruz A
Br J Pharmacol; 2009 Apr; 156(8):1218-27. PubMed ID: 19222481
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.
Berbée JF; Wong MC; Wang Y; van der Hoorn JW; Khedoe PP; van Klinken JB; Mol IM; Hiemstra PS; Tsikas D; Romijn JA; Havekes LM; Princen HM; Rensen PC
J Nutr Biochem; 2013 Aug; 24(8):1423-30. PubMed ID: 23337345
[TBL] [Abstract][Full Text] [Related]
13. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
Tsujita K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Yamanaga K; Komura N; Sakamoto K; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
J Am Coll Cardiol; 2015 Aug; 66(5):495-507. PubMed ID: 26227186
[TBL] [Abstract][Full Text] [Related]
14. Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms.
Wang JA; Chen WA; Wang Y; Zhang S; Bi H; Hong B; Luo Y; Daugherty A; Xie X
Atherosclerosis; 2011 Jul; 217(1):90-6. PubMed ID: 21481872
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of intestinal cholesterol absorption decreases atherosclerosis but not adipose tissue inflammation.
Umemoto T; Subramanian S; Ding Y; Goodspeed L; Wang S; Han CY; Teresa AS; Kim J; O'Brien KD; Chait A
J Lipid Res; 2012 Nov; 53(11):2380-9. PubMed ID: 22956784
[TBL] [Abstract][Full Text] [Related]
16. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture.
Roth L; Rombouts M; Schrijvers DM; Martinet W; De Meyer GR
Vascul Pharmacol; 2016 May; 80():50-8. PubMed ID: 26826559
[TBL] [Abstract][Full Text] [Related]
18. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
[TBL] [Abstract][Full Text] [Related]
19. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
20. Dietary cholesterol oxidation products accelerate plaque destabilization and rupture associated with monocyte infiltration/activation via the MCP-1-CCR2 pathway in mouse brachiocephalic arteries: therapeutic effects of ezetimibe.
Sato K; Nakano K; Katsuki S; Matoba T; Osada K; Sawamura T; Sunagawa K; Egashira K
J Atheroscler Thromb; 2012; 19(11):986-98. PubMed ID: 22785139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
